Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA

Risks for sepsis and colectomy during the first twelve months of C. Difficile as well as additional burdens on the healthcare system. Novel therapies are also discussed.

Explanation of the cost-effectiveness analysis and additional factors involved when treating C. Difficile with REBYOTA.

Overview of Markov model, a tool used for calculating potential clinical outcomes and the associated costs, and its use in the REBYOTA study. The standard of care used in the study is also defined.

Brief rundown of patient demographics involved in REBYOTA trials and this cost-effectiveness analysis.

Discussion on cost inputs involved in the cost-efficiency analysis which includes: medication cost, REBYOTA cost, imaging cost, out-patient visit costs, and more.

Overview of bias toward patients with C. Difficile, plus an overview of commercial insurances vs Medicare in treatment of C. Difficile.